Silicon Valley firm BioIntelliSense announced the advancement of its medical-grade biosensor product portfolio and Data-as-a-Service (DaaS) platform with the introduction of the BioButton™ device. The BioButton is a coin-sized, disposable medical device that measures continuous temperature and other vital signs in patients at home, high-risk individuals, frontline healthcare professionals for a remarkable 90 days, and enables their safe return to work and school.
BioIntelliSense’s BioButton medical-grade device and HIPAA-compliant data services enable effortless remote data capture and continuous multi-parameter monitoring of temperature, respiratory rate and heart rate at rest, body position, sleep and activity state for 90-days on a single disposable on-body sensor, says a press release.
“The introduction of the BioButton device, in combination with the BioMobile applications and enterprise triage dashboards, represents a significant advancement in making continuous medical-grade monitoring reliable, effortless and cost-effective,” said James Mault, MD, CEO of BioIntelliSense. “The convenience of the BioButton will support a range of clinical use cases for RPM reimbursement and mass-market use to enable safe return to work or school.”
The BioIntelliSense DaaS platform can be successfully applied to a wide range of COVID-19 related use cases for the monitoring of returning workforce and students, high-risk patient populations, patients in-hospital and in-home along with frontline healthcare professionals.
BioIntelliSense is ushering in a new era of continuous health monitoring and clinical intelligence for Remote Patient Monitoring (RPM). The company offers medical-grade data services that allow for early detection of adverse trends through its proprietary biosensor technology and advanced analytics at a fraction of the cost of spot temperature measurements or traditional Remote Patient Monitoring (RPM) systems. Its medical-grade Data-as-a-Service (DaaS) platform seamlessly captures multi-parameter vital signs, physiological biometrics and symptomatic events through effortless patient experience. The FDA-cleared BioSticker™ and BioButton™ devices make remote monitoring and early detection simple. Through the platform’s advanced analytics, clinicians will now have access to high-resolution patient trending and reporting to enable medical-grade care at home.